Clinical Pharmacokinetics and Pharmacodynamics of Marstacimab, an Anti-tissue Factor Pathway Inhibitor Monoclonal Antibody, in Adolescent and Adult Participants with Hemophilia
Satyaprakash Nayak, Akiyuki Suzuki, Patanjali Ravva, Sangeeta Raje · 2026
Read Clinical Pharmacokinetics and Pharmacodynamics of Marstacimab, an Anti-tissue Factor Pathway Inhibitor Monoclonal Antibody, in Adolescent and Adult Participants with Hemophilia by Satyaprakash Nayak, Akiyuki Suzuki, Patanjali Ravva, Sangeeta Raje (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13624058.txt.
Description
Satyaprakash Nayak and co-authors model how a hemophilia antibody acts in the body in a 2026 study. Marstacimab blocks a natural brake on clotting, which helps blood clot despite missing factors. It is dosed under the skin to prevent bleeds. Dosing must fit teens and adults alike.
Data pooled 213 people from six trials, both healthy volunteers and patients. Doses spanned a wide range by injection. A mixed-effects model linked drug levels to levels of its target and to peak thrombin output. Body weight proved the key factor shaping drug levels. Age had no relevant effect once weight was counted. The model supports weight-aware dosing in practice.
Catalog record
| CREATOR | Satyaprakash Nayak, Akiyuki Suzuki, Patanjali Ravva, Sangeeta Raje |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 92 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |